Endometrial Cancer:2021 

Thank you for sharing this information 🙏🏻

In April 221, The FDA has granted an accelerated approval to dostarlimab-gxly (Jemperli) for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers are mismatch repair deficient (dMMR), as determined by an FDA-approved test.1,2 The approval is based on results from the dMMR endometrial cancer cohort of the multicenter, single-arm, multiple parallel-cohort, open-label GARNET study, in which dostarlimab elicited a 42.3% objective response rate (ORR) in 71 patients with dMMR recurrent or advanced endometrial cancer. This included a 12.7% complete response (CR) rate and a 29.6% partial response (PR) rate. The duration of response (DOR) was at least 6 months for 93.3% of responders, and the median DOR was not reached at a median follow-up of 14.1 months (2.6-22.4+).

교수님 안녕하세요? 죄송하지만 교수님의 고견을 듣고 싶어서 결절성 림프구 우세형2기로 abvd 6회세트로 다 맞고 올 해 3월말에 관해판정 받았는데 6월 조직검사에서 같은 아형으로 재발했어요. 이런 경우에 자가조혈모 이식을 꼭 해야하나요? 불임 확률도 100% 라는데요

Pembrolizumab in combination of carboplatin and paclitaxel improved DFS substantially in advanced or recurrent/ metastatic endometrial cancer. www.nejm.org/doi/full/10.1056/NEJMoa2302312

교수님, 잘 지내시나요? 건강하십시오!

🙏🏽😌

Dr, Kim what great information! Dr. Kim was my physician for 15 years! He is the most caring and knowledgeable doctor I have ever come across. Based on my personal experience his information will be 100% accurate so no need to look any further. Make sure to subscribe to his channel and hit the like button so others can find his videos faster!

Hair straightener increases the risk of endometrial cancer. academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac165/6759686?login=false There is a news report that 5 hair straightener companies were sued by patients.